• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic touts Micra leadless pacer post-approval registry study data

Medtronic touts Micra leadless pacer post-approval registry study data

May 9, 2018 By Fink Densford

Medtronic's Micra TPS

Medtronic (NYSE:MDT) today released one-year results from the post-approval registry study of its Micra leadless transcatheter pacing system, touting a high implant success rate and a low complication rate.

Results from the study are slated to be presented tomorrow at the Heart Rhythm Society’s annual scientific sessions conference in Boston, the Fridley, Minn.-based company said.

Medtronic’s Micra pacemaker is approximately 1/10th the size of a conventional pacemaker, and is designed to be implanted via catheter into the right ventricle to deliver single-chamber pacing. The system features a battery with an estimated 12-year battery lifespan, and is cleared for use with full-body MRI scans. The FDA approved Micra in April 2016.

The post-approval registry study examined data from 1,817 patients across 23 countries compared to a reference dataset of 2,667 patients with transvenous pacemakers.

“Medtronic is committed to providing the most advanced technologies that improve lives of patients around the world. The leadless Micra pacemaker is an excellent example of one of those technologies, and now we know that it performs well for patients in a real world setting as well as in a clinical trial,” Medtronic cardiac rhythm and heart failure division chief medical officer Dr. Rob Kowal said in a press release.

New data from the registry study indicated that the Micra system had an implant success rate of 99.1% with a major complication rate of 2.7% through one year. Procedures to implant the device were reported as having a 63% lower risk for major complication compared to traditional pacing systems, Medtronic said, with the risk of major complication trending lower in the post-approval study than in its earlier investigational study.

Medtronic said that data from the study indicated the Micra system was a safe and feasible pacing option for patients with recent cardiac implantable electronic device infections, with 98 of 99 such patients undergoing successful Micra implantation attempts, according to the study.

“The results from the post-approval registry are consistent with the positive outcomes reported with previous Micra TPS data. The high implant success and low major complication rates in a real-world patient population with new Micra implanters reinforce the safety and performance of the Micra TPS. By eliminating the need for leads and a subcutaneous pocket, miniaturized leadless pacemakers are associated with a low-risk of device-related infection. These new data show that this novel technology may provide a safe option for patients with prior device-related infections,” Dr. Mikhael El-Chami of Atlanta’s Emory University School of Medicine said in a prepared statement.

Earlier this month, Medtronic issued a select recall for specific Covidien Endo GIA staplers over possible missing components, according to a safety field notice from the company.

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Structural Heart Tagged With: Medtronic

More recent news

  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership
  • Aurora Spine begins first procedures with Aero lumbar fusion system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy